PMID- 27121061
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20220331
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 21
DP  - 2016 May 24
TI  - Differential expression of major histocompatibility complex class I in subtypes 
      of breast cancer is associated with estrogen receptor and interferon signaling.
PG  - 30119-32
LID - 10.18632/oncotarget.8798 [doi]
AB  - Tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC) 
      have a strong prognostic and predictive significance. However, the mechanism of 
      TIL influx in TNBC is unclear. Expression of major histocompatibility complex 
      class I (MHC I) on the tumor cell is essential for the effective killing of tumor 
      by cytotoxic TILs. In our current study, human leukocyte antigen (HLA) expression 
      was inversely correlated with estrogen receptor (ER) expression in normal and 
      cancerous breast tissue and positively correlated with TILs in breast cancer. The 
      ER score was inversely correlated with TILs in breast cancer. HLA-A and CD8B gene 
      expression was negatively correlated with ESR1 and positively correlated with 
      interferon-associated gene expression in The Cancer Genome Atlas (TCGA) data. 
      Negative correlation between ESR1 and HLA and positive correlation between 
      interferon-associated and HLA gene expression were also confirmed in Cancer Cell 
      Line Encyclopedia (CCLE) data. Taken together, our data suggest that a lower 
      expression of HLA in luminal-type tumors might be associated with low level of 
      TILs in those tumors. Further investigation of the mechanism of higher HLA 
      expression and TIL influx in TNBC may help to boost the host immune response.
FAU - Lee, Hee Jin
AU  - Lee HJ
AD  - Department of Pathology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Song, In Hye
AU  - Song IH
AD  - Department of Pathology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Park, In Ah
AU  - Park IA
AD  - Department of Pathology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Heo, Sun-Hee
AU  - Heo SH
AD  - Department of Pathology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Kim, Young-Ae
AU  - Kim YA
AD  - Department of Pathology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Ahn, Jin-Hee
AU  - Ahn JH
AD  - Department of Oncology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Gong, Gyungyub
AU  - Gong G
AD  - Department of Pathology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (CD8 Antigens)
RN  - 0 (CD8beta antigen)
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Receptors, Progesterone)
RN  - 9008-11-1 (Interferons)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast/pathology
MH  - CD8 Antigens/*metabolism
MH  - Cell Line, Tumor
MH  - Disease-Free Survival
MH  - Estrogen Receptor alpha/*metabolism
MH  - Female
MH  - HLA-A Antigens/immunology/*metabolism
MH  - HLA-B Antigens/immunology/*metabolism
MH  - HLA-C Antigens/immunology/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Interferons/metabolism
MH  - Lymphatic Metastasis
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Mutation
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Tissue Array Analysis
MH  - Triple Negative Breast Neoplasms/genetics/*immunology/mortality/pathology
PMC - PMC5058668
OTO - NOTNLM
OT  - Pathology Section
OT  - breast carcinoma
OT  - human leukocyte antigen
OT  - major histocompatibility complex I
OT  - tumor-infiltrating lymphocytes
COIS- All authors declare no conflicts of interest.
EDAT- 2016/04/29 06:00
MHDA- 2017/12/30 06:00
PMCR- 2016/05/24
CRDT- 2016/04/29 06:00
PHST- 2015/12/14 00:00 [received]
PHST- 2016/04/03 00:00 [accepted]
PHST- 2016/04/29 06:00 [entrez]
PHST- 2016/04/29 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2016/05/24 00:00 [pmc-release]
AID - 8798 [pii]
AID - 10.18632/oncotarget.8798 [doi]
PST - ppublish
SO  - Oncotarget. 2016 May 24;7(21):30119-32. doi: 10.18632/oncotarget.8798.